Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Other Non-Current Liabilities (2023)

Zenas BioPharma (ZBIO) has 1 years of Other Non-Current Liabilities data on record, last reported at $20.3 million in Q4 2023.

  • For Q4 2023, Other Non-Current Liabilities changed N/A year-over-year to $20.3 million; the TTM value through Dec 2023 reached $20.3 million, changed N/A, while the annual FY2023 figure was $20.3 million, N/A changed from the prior year.
  • Other Non-Current Liabilities reached $20.3 million in Q4 2023 per ZBIO's latest filing.
  • Across five years, Other Non-Current Liabilities topped out at $20.3 million in Q4 2023 and bottomed at $20.3 million in Q4 2023.